Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Clinical and Experimental Hematopathology 2014, Vol.54(2), pp.117-127
Hauptverfasser:	Goto, Naoe, Tsurumi, Hisashi, Takemura, Masao, Matsumoto, Takuro, Shibata, Yuhei, Mabuchi, Ryoko, Nakamura, Nobuhiko, Nakamura, Hiroshi, Yamada, Tetsuya, Seishima, Mitsuru, Takami, Tsuyoshi, Takeuchi, Tamotsu, Moriwaki, Hisataka
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - therapeutic use diffuse large B-cell lymphoma Doxorubicin - therapeutic use Female Humans Lymphatic Metastasis lymphoma Lymphoma, Large B-Cell, Diffuse - blood Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Neoplasm Staging Prednisone - therapeutic use Prognosis prognostic factor Receptors, Tumor Necrosis Factor, Type I - blood ROC Curve soluble tumor necrosis factor receptor 1 Treatment Outcome Vincristine - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!